Rocket Pharmaceuticals (RCKT) Free Cash Flow (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Free Cash Flow of -$45.5 million for Q1 2026, down 30.26% sequentially from -$34.9 million in Q4 2025, and up 18.54% YoY from -$38.4 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Free Cash Flow (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Free Cash Flow for 13 years, with the latest figure at -$45.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 18.54% year-over-year to -$45.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$180.1 million (up 15.26% YoY) and the FY2025 annual result came in at -$190.5 million, up 11.66% from the prior year.
- Free Cash Flow fell to -$45.5 million in Q1 2026 per RCKT's latest filing, from -$34.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$34.9 million in Q4 2025 and troughed at -$59.4 million in Q1 2023.
- A 5-year average of -$49.6 million and a median of -$50.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 67.32% in 2022, then jumped 33.54% in 2025.
- Over 5 years, Free Cash Flow stood at -$52.8 million in 2022, then grew by 16.41% to -$44.1 million in 2023, then retreated by 19.12% to -$52.5 million in 2024, then surged by 33.54% to -$34.9 million in 2025, then sank by 30.26% to -$45.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$45.5 million, -$34.9 million, and -$50.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | -39.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.62 Mn |
| Jun 30, 2026 | -39.62 Mn |
| Mar 31, 2026 | -45.49 Mn |
| Mar 31, 2026 | -45.49 Mn |
| Dec 31, 2025 | -34.92 Mn |
| Dec 31, 2025 | -34.92 Mn |
| Sep 30, 2025 | -50.78 Mn |
| Sep 30, 2025 | -50.78 Mn |
| Jun 30, 2025 | -48.91 Mn |
| Jun 30, 2025 | -48.91 Mn |
| Mar 31, 2025 | -55.84 Mn |
| Mar 31, 2025 | -55.84 Mn |
| Dec 31, 2024 | -52.54 Mn |
| Dec 31, 2024 | -52.54 Mn |
| Sep 30, 2024 | -48.40 Mn |
| Sep 30, 2024 | -48.40 Mn |
| Jun 30, 2024 | -55.75 Mn |
| Jun 30, 2024 | -55.75 Mn |
| Mar 31, 2024 | -58.89 Mn |
| Mar 31, 2024 | -58.89 Mn |